ZVRA (Zevra Therapeutics) Other Current Receivables: $12.2 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZVRA Zevra Therapeutics Inc ZVRA
69 GF Score
Price $11.25
GF Value $20.92
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Zevra Therapeutics Other Current Receivables?

Zevra Therapeutics ZVRA -1.66% 69 Other Current Receivables is $12.2 Mil as of Jun. 2026. GuruFocus rates ZVRA with a GF Score™ of 69/100 and a GF Value™ of $20.92 (Possible Value Trap). The stock has 5 warning signs investors should review.

Zevra Therapeutics's Other Current Receivables for the quarter that ended in Jun. 2026 was $12.2 Mil.

Zevra Therapeutics's quarterly Other Current Receivables increased from Dec. 2025 ($13.38 Mil) to Mar. 2026 ($14.45 Mil) but then stayed the same from Mar. 2026 ($14.45 Mil) to Jun. 2026 ($12.16 Mil).

Zevra Therapeutics's annual Other Current Receivables increased from Dec. 2023 ($1.26 Mil) to Dec. 2024 ($6.50 Mil) and increased from Dec. 2024 ($6.50 Mil) to Dec. 2025 ($13.38 Mil).

Zevra Therapeutics Other Current Receivables Related Terms

Zevra Therapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Zevra Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zevra Therapeutics Other Current Receivables Chart

Zevra Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 1.11 1.26 6.50 13.38

Zevra Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.47 8.07 13.38 14.45 12.16
ZVRA
69GF Score
Zevra Therapeutics Inc ZVRA
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zevra Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $12.2 Mil mean?
Zevra Therapeutics (ZVRA) has a Other Current Receivables of $12.2 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Zevra Therapeutics and its competitors.
Is Zevra Therapeutics' Other Current Receivables too high?
Zevra Therapeutics' current Other Current Receivables is $12.2 Mil. Overall, Zevra Therapeutics has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zevra Therapeutics' Other Current Receivables compare to TECX and RLMD?
Zevra Therapeutics' Other Current Receivables of $12.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Zevra Therapeutics and its competitors. Zevra Therapeutics's current Other Current Receivables is $12.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zevra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zevra Therapeutics (ZVRA) is currently considered Possible Value Trap. The stock's GF Value™ is $20.92, compared to a current price of $11.25 — trading 46.2% below its estimated fair value. The current Other Current Receivables is $12.2 Mil. Zevra Therapeutics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Zevra Therapeutics (ZVRA), the current Other Current Receivables is $12.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zevra Therapeutics (ZVRA) Overvalued in 2026?

Based on GuruFocus' analysis, Zevra Therapeutics stock appears to be undervalued. The current stock price of $11.25 is trading 46.2% below its estimated GF Value™ of $20.92. GuruFocus considers Zevra Therapeutics to be Possible Value Trap.

Key valuation signals for ZVRA:

  • Other Current Receivables: $12.2 Mil
  • GF Value™: $20.92 vs. price of $11.25 (46.2% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the ZVRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zevra Therapeutics Business Description

Other Exchanges 1GDA:Germany
Address 101 Federal Street, Boston, MA, USA, 02110
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
69GF Score

Get the complete analysis for ZVRA

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.25
Price
$20.92
GF Value